These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 38601120)

  • 1. Preventing hyperhomocysteinemia using vitamin B
    Redonnet-Vernhet I; Mercié P; Lebreton L; Blouin JM; Bronnimann D; Mesli S; Guibet C; Ribeiro E; Gensous N; Duffau P; Gouya L; Richard E
    Mol Genet Metab Rep; 2024 Jun; 39():101076. PubMed ID: 38601120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperhomocysteinemia in acute hepatic porphyria (AHP) and implications for treatment with givosiran.
    Ventura P; Sardh E; Longo N; Balwani M; Plutzky J; Gouya L; Phillips J; Rhyee S; Fanelli MJ; Sweetser MT; Petrides PE
    Expert Rev Gastroenterol Hepatol; 2022 Sep; 16(9):879-894. PubMed ID: 35929959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria.
    Sardh E; Harper P
    J Intern Med; 2022 May; 291(5):593-610. PubMed ID: 35067977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated homocysteine is negatively correlated with plasma cystathionine β-synthase activity in givosiran-treated patients.
    Keibler MA; Sridharan GV; Sweetser MT; Ticau S
    JIMD Rep; 2024 Jul; 65(4):262-271. PubMed ID: 38974609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dysregulation of homocysteine homeostasis in acute intermittent porphyria patients receiving heme arginate or givosiran.
    To-Figueras J; Wijngaard R; García-Villoria J; Aarsand AK; Aguilera P; Deulofeu R; Brunet M; Gómez-Gómez À; Pozo OJ; Sandberg S
    J Inherit Metab Dis; 2021 Jul; 44(4):961-971. PubMed ID: 33861472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe homocysteinemia in two givosiran-treated porphyria patients: is free heme deficiency the culprit?
    Petrides PE; Klein M; Schuhmann E; Torkler H; Molitor B; Loehr C; Obermeier Z; Beykirch MK
    Ann Hematol; 2021 Jul; 100(7):1685-1693. PubMed ID: 34050373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case Report: Lack of Response to Givosiran in a Case of ALAD Porphyria.
    Graff E; Anderson KE; Levy C
    Front Genet; 2022; 13():867856. PubMed ID: 35991568
    [No Abstract]   [Full Text] [Related]  

  • 8. Givosiran for the treatment of acute hepatic porphyria.
    Ricci A; Ventura P
    Expert Rev Clin Pharmacol; 2022 Apr; 15(4):383-393. PubMed ID: 35531651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria.
    Balwani M; Sardh E; Ventura P; Peiró PA; Rees DC; Stölzel U; Bissell DM; Bonkovsky HL; Windyga J; Anderson KE; Parker C; Silver SM; Keel SB; Wang JD; Stein PE; Harper P; Vassiliou D; Wang B; Phillips J; Ivanova A; Langendonk JG; Kauppinen R; Minder E; Horie Y; Penz C; Chen J; Liu S; Ko JJ; Sweetser MT; Garg P; Vaishnaw A; Kim JB; Simon AR; Gouya L;
    N Engl J Med; 2020 Jun; 382(24):2289-2301. PubMed ID: 32521132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria.
    Sardh E; Harper P; Balwani M; Stein P; Rees D; Bissell DM; Desnick R; Parker C; Phillips J; Bonkovsky HL; Vassiliou D; Penz C; Chan-Daniels A; He Q; Querbes W; Fitzgerald K; Kim JB; Garg P; Vaishnaw A; Simon AR; Anderson KE
    N Engl J Med; 2019 Feb; 380(6):549-558. PubMed ID: 30726693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Givosiran in acute intermittent porphyria: A personalized medicine approach.
    Poli A; Schmitt C; Moulouel B; Mirmiran A; Talbi N; Rivière S; Cerutti D; Bouchoule I; Faivre A; Grobost V; Douillard C; Duchêne F; Fiorentino V; Dupré T; Manceau H; Peoc'h K; Puy H; Lefebvre T; Gouya L
    Mol Genet Metab; 2022 Mar; 135(3):206-214. PubMed ID: 35058124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperhomocysteinemia in patients with acute porphyrias: A potentially dangerous metabolic crossroad?
    Ventura P; Corradini E; Di Pierro E; Marchini S; Marcacci M; Cuoghi C; Buzzetti E; Pietrangelo A
    Eur J Intern Med; 2020 Sep; 79():101-107. PubMed ID: 32487371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spotlight on Givosiran as a Treatment Option for Adults with Acute Hepatic Porphyria: Design, Development, and Place in Therapy.
    Majeed CN; Ma CD; Xiao T; Rudnick S; Bonkovsky HL
    Drug Des Devel Ther; 2022; 16():1827-1845. PubMed ID: 35734365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperhomocysteinemia in patients with acute porphyrias: a possible effect of ALAS1 modulation by siRNAm therapy and its control by vitamin supplementation.
    Ricci A; Marcacci M; Cuoghi C; Pietrangelo A; Ventura P
    Eur J Intern Med; 2021 Oct; 92():121-123. PubMed ID: 34226116
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study.
    Ventura P; Bonkovsky HL; Gouya L; Aguilera-Peiró P; Montgomery Bissell D; Stein PE; Balwani M; Anderson DKE; Parker C; Kuter DJ; Monroy S; Oh J; Ritchie B; Ko JJ; Hua Z; Sweetser MT; Sardh E;
    Liver Int; 2022 Jan; 42(1):161-172. PubMed ID: 34717041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leading RNA Interference Therapeutics Part 2: Silencing Delta-Aminolevulinic Acid Synthase 1, with a Focus on Givosiran.
    de Paula Brandão PR; Titze-de-Almeida SS; Titze-de-Almeida R
    Mol Diagn Ther; 2020 Feb; 24(1):61-68. PubMed ID: 31792921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of givosiran for acute hepatic porphyria: Final results of the randomized phase III ENVISION trial.
    Kuter DJ; Bonkovsky HL; Monroy S; Ross G; Guillén-Navarro E; Cappellini MD; Minder AE; Hother-Nielsen O; Ventura P; Jia G; Sweetser MT; Thapar M;
    J Hepatol; 2023 Nov; 79(5):1150-1158. PubMed ID: 37479139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review.
    Wang B; Bonkovsky HL; Lim JK; Balwani M
    Gastroenterology; 2023 Mar; 164(3):484-491. PubMed ID: 36642627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up of givosiran treatment in patients with acute intermittent porphyria from a phase 1/2, 48-month open-label extension study.
    Sardh E; Balwani M; Rees DC; Anderson KE; Jia G; Sweetser MT; Wang B
    Orphanet J Rare Dis; 2024 Oct; 19(1):365. PubMed ID: 39363243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Givosiran to treat acute porphyria.
    Honor A; Rudnick SR; Bonkovsky HL
    Drugs Today (Barc); 2021 Jan; 57(1):47-59. PubMed ID: 33594389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.